{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T23:08:22Z","timestamp":1776121702693,"version":"3.50.1"},"reference-count":30,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Z Geburtshilfe Neonatol"],"published-print":{"date-parts":[[2026,4]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Anti-M\u00fcllerian hormone (AMH) is commonly used in artificial reproductive\n                        treatments. Unfortunately, there is only limited data about AMH in adverse\n                        pregnancy outcomes. Here, we searched the role of first-trimester AMH to\n                        predict adverse pregnancy outcomes in women without polycystic ovary\n                        syndrome (PCOS).<\/jats:p>\n                  <jats:p>A total of 240 pregnant women were enrolled in this prospective study. The\n                        inclusion criteria were being in the first trimester of pregnancy, having\n                        AMH levels measured, not having PCOS, and having had regular antenatal\n                        visits. Adverse outcomes were preeclampsia, gestational hypertension,\n                        gestational diabetes, preterm birth, pregnancy loss, and stillbirth.\n                        Demographic features, obstetric outcomes, and AMH levels were recorded and\n                        compared for each adverse outcome.<\/jats:p>\n                  <jats:p>AMH levels were lower in preeclampsia, gestational hypertension, gestational\n                        diabetes, and pregnancy loss compared to the control group. In ROC analysis,\n                        a cut-off value of 2.14 ng\/mL for predicting preeclampsia yielded a\n                        sensitivity of 84.2% and specificity of 55.5% (p=0.027, AUC=0.658). For\n                        gestational hypertension, a threshold of 2.65 ng\/mL resulted in a\n                        sensitivity of 94.4% and specificity of 41.2% (p=0.004, AUC=0.662). In\n                        predicting gestational diabetes, a cut-off of 1.98 ng\/mL achieved a\n                        sensitivity of 83.3% and specificity of 59.7% (p&lt;0.001, AUC=0.723). For\n                        pregnancy loss, a cut-off value of 2.94 ng\/mL showed a sensitivity of 93.8%\n                        and specificity of 33.6% (p=0.001, AUC=0.660).<\/jats:p>\n                  <jats:p>The study provides initial indications about the role of AMH in predicting\n                        adverse pregnancy outcomes in pregnant women without PCOS. We believe that\n                        our study, when supported by randomized controlled studies with a large\n                        population, could confirm first-trimester AMH as a biomarker that can be\n                        used to predict adverse pregnancy outcomes. By using this marker, patients\n                        can be informed about the complications that will develop in the later\n                        period of pregnancy and can be referred to appropriate centers.<\/jats:p>","DOI":"10.1055\/a-2743-4575","type":"journal-article","created":{"date-parts":[[2025,11,27]],"date-time":"2025-11-27T00:17:46Z","timestamp":1764202666000},"page":"103-108","source":"Crossref","is-referenced-by-count":0,"title":["Early Anti-M\u00fcllerian Hormone Levels in Adverse Pregnancy Outcomes in\n                    Women without Polycystic Ovary Syndrome"],"prefix":"10.1055","volume":"230","author":[{"given":"Ferhan","family":"Zengin Sadef","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, Yozgat State Hospital,\n                    Yozgat, Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berke","family":"Yesiltas","sequence":"additional","affiliation":[{"name":"Obstetrics and Gynecology, Afyon Suhut State Hospital, Afyon,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Burcu","family":"Dincgez","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Bursa Yuksek\n                    Ihtisas Research and Training Hospital, University of Health Sciences, Bursa,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gulten","family":"Ozgen","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Bursa Yuksek\n                    Ihtisas Research and Training Hospital, University of Health Sciences, Bursa,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tayfur","family":"Cift","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Nev Esentepe Hospital, Bursa,\n                    Turkey"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2025,11,26]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1055\/s-0044-1786732","article-title":"The role of Anti-M\u00fcllerian hormone in ovarian function","volume":"42","author":"S Yildiz","year":"2024","journal-title":"Semin Reprod Med"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"719029","DOI":"10.3389\/fendo.2021.719029","article-title":"Variation in the measurement of anti-M\u00fcllerian hormone \u2013 What are the laboratory\n                    issues?","volume":"12","author":"R Punchoo","year":"2021","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"7209","DOI":"10.3390\/jcm11237209","article-title":"Clinical utilities of anti-M\u00fcllerian hormone","volume":"11","author":"N Russell","year":"2022","journal-title":"J Clin Med"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"1468364","DOI":"10.3389\/fendo.2024.1468364","article-title":"Anti-M\u00fcllerian hormone: biology and role in endocrinology and cancers","volume":"15","author":"M Gowkielewicz","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1111\/cen.12557","article-title":"Polycystic ovary syndrome and anti-M\u00fcllerian hormone: role of insulin\n                    resistance, androgens, obesity and gonadotrophins","volume":"81","author":"S Cassar","year":"2014","journal-title":"Clin Endocrinol (Oxf)"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"641","DOI":"10.3389\/fendo.2020.00641","article-title":"Role of anti-M\u00fcllerian hormone in the pathogenesis of polycystic ovary\n                    syndrome","volume":"11","author":"D Dewailly","year":"2020","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1186\/1477-7827-11-60","article-title":"Anti-Mullerian-hormone levels during pregnancy and postpartum","volume":"11","author":"A K\u00f6ninger","year":"2013","journal-title":"Reprod Biol Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1093\/humrep\/deh819","article-title":"Anti-M\u00fcllerian hormone concentrations in maternal serum during pregnancy","volume":"20","author":"A La Marca","year":"2005","journal-title":"Hum Reprod"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"e220128","DOI":"10.1530\/RAF-22-0128","article-title":"Serum anti-m\u00fcllerian hormone (AMH) concentration during pregnancy: a\n                    longitudinal study","volume":"4","author":"S McCredie","year":"2023","journal-title":"Reprod Fertil"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"333","DOI":"10.4274\/balkanmedj.galenos.2024.2024-7-108","article-title":"Hypertensive disorders of pregnancy: Diagnosis, management and timing of\n                    birth","volume":"41","author":"C \u0130nan","year":"2024","journal-title":"Balkan Med J"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1097\/OGX.0000000000000899","article-title":"Diagnosis and management of gestational diabetes mellitus: An overview of\n                    national and international guidelines","volume":"76","author":"I Tsakiridis","year":"2021","journal-title":"Obstet Gynecol Surv"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1111\/jog.13925","article-title":"Pregnancy outcomes of antibody negative and untreated subclinical\n                    hypothyroidism","volume":"45","author":"B D Cakmak","year":"2019","journal-title":"J Obstet Gynaecol Res"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1093\/molehr\/gah015","article-title":"Anti-M\u00fcllerian hormone expression pattern in the human ovary: potential\n                    implications for initial and cyclic follicle recruitment","volume":"10","author":"C Weenen","year":"2004","journal-title":"Mol Hum Reprod"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1093\/humupd\/dmp036","article-title":"Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive\n                    technology (ART)","volume":"16","author":"A La Marca","year":"2010","journal-title":"Hum Reprod Update"},{"key":"ref15","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s13224-020-01362-0","article-title":"AMH and its clinical implications","volume":"70","author":"L Shrikhande","year":"2020","journal-title":"J Obstet Gynaecol India"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/ajo.12183","article-title":"Evaluation of anti-Mullerian hormone in the first trimester as a predictor for\n                    hypertensive disorders of pregnancy and other adverse pregnancy outcomes","volume":"54","author":"A W Shand","year":"2014","journal-title":"Aust N Z J Obstet Gynaecol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.rbmo.2019.02.004","article-title":"Pregnancy and neonatal complications in women with polycystic ovary syndrome in\n                    relation to second-trimester anti-M\u00fcllerian hormone levels","volume":"39","author":"R Valdimarsdottir","year":"2019","journal-title":"Reprod Biomed Online"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"1081069","DOI":"10.3389\/fendo.2023.1081069","article-title":"Serum anti-M\u00fcllerian hormone levels are associated with perinatal outcomes in\n                    women undergoing IVF\/ICSI: A multicenter retrospective cohort study","volume":"14","author":"Y C He","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3109\/14767058.2014.955007","article-title":"May maternal anti-mullerian hormone levels predict adverse maternal and\n                    perinatal outcomes in preeclampsia?","volume":"28","author":"A Tokmak","year":"2015","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1016\/j.tjog.2019.01.003","article-title":"Serum anti-mullerian hormone and renalase levels in predicting the risk of\n                    preeclampsia","volume":"58","author":"Z Jamil","year":"2019","journal-title":"Taiwan J Obstet Gynecol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1186\/s13104-017-2544-6","article-title":"Maternal serum anti-M\u00fcllerian hormone in Sudanese women with preeclampsia","volume":"10","author":"E Agabain","year":"2017","journal-title":"BMC Res Notes"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"865","DOI":"10.3109\/14767058.2014.937418","article-title":"Maternal serum anti-M\u00fcllerian hormone at 11\u201313 weeks' gestation in the\n                    prediction of preeclampsia","volume":"28","author":"C Birdir","year":"2015","journal-title":"J Matern Fetal Neonatal Med"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"e1116","DOI":"10.1210\/clinem\/dgae324","article-title":"High AMH levels are associated with gestational hypertension in patients with\n                    PCOS who underwent IVF\/ICSI-ET","volume":"110","author":"M Zhang","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"ref24","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1080\/09513590.2017.1359824","article-title":"Anti-M\u00fcllerian hormone in type 2 and gestational diabetes during the second half\n                    of pregnancy: relationship with sexual steroid levels and metabolic\n                    parameters","volume":"34","author":"C Villarroel","year":"2018","journal-title":"Gynecol Endocrinol"},{"key":"ref25","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1007\/s12020-014-0515-4","article-title":"Anti-mullerian hormone concentration during the third trimester of pregnancy and\n                    puerperium: a longitudinal case-control study in normal and diabetic\n                    pregnancy","volume":"50","author":"S Gerli","year":"2015","journal-title":"Endocrine"},{"key":"ref26","doi-asserted-by":"publisher","first-page":"518","DOI":"10.1016\/j.fertnstert.2017.07.001","article-title":"Serum antim\u00fcllerian hormone levels are independently related to miscarriage\n                    rates after in vitro fertilization-embryo transfer","volume":"108","author":"B Tarasconi","year":"2017","journal-title":"Fertil Steril"},{"key":"ref27","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1080\/19396368.2020.1806944","article-title":"The anti-Mullerian hormone as a predictor of early pregnancy loss in subfertile\n                    women","volume":"66","author":"S Hong","year":"2020","journal-title":"Syst Biol Reprod Med"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"600","DOI":"10.1080\/14647273.2021.1873431","article-title":"Is low anti-Mullerian hormone (AMH) level a risk factor of miscarriage in\n                    women<37 years old undergoing in vitro fertilization (IVF)?","volume":"25","author":"A S Cornille","year":"2022","journal-title":"Hum Fertil (Camb)"},{"key":"ref29","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1002\/ijgo.13104","article-title":"Anti-M\u00fcllerian hormone as a marker of abortion in the first trimester of\n                    spontaneous pregnancy","volume":"149","author":"M Kostrzewa","year":"2020","journal-title":"Int J Gynaecol Obstet"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"4215","DOI":"10.1210\/jc.2015-2474","article-title":"Is anti-M\u00fcllerian hormone associated with fecundability? Findings from the EAGeR\n                    Trial","volume":"100","author":"S M Zarek","year":"2015","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Zeitschrift f\u00fcr Geburtshilfe und Neonatologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-2743-4575.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T22:32:52Z","timestamp":1776119572000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-2743-4575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,26]]},"references-count":30,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2026,4,13]]},"published-print":{"date-parts":[[2026,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-2743-4575","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0948-2393","1439-1651"],"issn-type":[{"value":"0948-2393","type":"print"},{"value":"1439-1651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,26]]}}}